224 related articles for article (PubMed ID: 31379857)
1. Increased NK Cell Count in Multiple Sclerosis Patients Treated With Dimethyl Fumarate: A 2-Year Longitudinal Study.
Marastoni D; Buriani A; Pisani AI; Crescenzo F; Zuco C; Fortinguerra S; Sorrenti V; Marenda B; Romualdi C; Magliozzi R; Monaco S; Calabrese M
Front Immunol; 2019; 10():1666. PubMed ID: 31379857
[No Abstract] [Full Text] [Related]
2. Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS.
Fleischer V; Friedrich M; Rezk A; Bühler U; Witsch E; Uphaus T; Bittner S; Groppa S; Tackenberg B; Bar-Or A; Zipp F; Luessi F
Mult Scler; 2018 Apr; 24(5):632-641. PubMed ID: 28436295
[TBL] [Abstract][Full Text] [Related]
3. Dimethyl fumarate induces changes in B- and T-lymphocyte function independent of the effects on absolute lymphocyte count.
Longbrake EE; Cantoni C; Chahin S; Cignarella F; Cross AH; Piccio L
Mult Scler; 2018 May; 24(6):728-738. PubMed ID: 28480794
[TBL] [Abstract][Full Text] [Related]
4. Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.
Longbrake EE; Ramsbottom MJ; Cantoni C; Ghezzi L; Cross AH; Piccio L
Mult Scler; 2016 Jul; 22(8):1061-1070. PubMed ID: 26459150
[TBL] [Abstract][Full Text] [Related]
5. Relapsing-Remitting Multiple Sclerosis Is Characterized by a T Follicular Cell Pro-Inflammatory Shift, Reverted by Dimethyl Fumarate Treatment.
Cunill V; Massot M; Clemente A; Calles C; Andreu V; Núñez V; López-Gómez A; Díaz RM; Jiménez MLR; Pons J; Vives-Bauzà C; Ferrer JM
Front Immunol; 2018; 9():1097. PubMed ID: 29896193
[TBL] [Abstract][Full Text] [Related]
6. Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice.
Mehta D; Miller C; Arnold DL; Bame E; Bar-Or A; Gold R; Hanna J; Kappos L; Liu S; Matta A; Phillips JT; Robertson D; von Hehn CA; Campbell J; Spach K; Yang L; Fox RJ
Neurology; 2019 Apr; 92(15):e1724-e1738. PubMed ID: 30918100
[TBL] [Abstract][Full Text] [Related]
7. Fingolimod and Dimethyl-Fumarate-Derived Lymphopenia is not Associated with Short-Term Treatment Response and Risk of Infections in a Real-Life MS Population.
Boffa G; Bruschi N; Cellerino M; Lapucci C; Novi G; Sbragia E; Capello E; Uccelli A; Inglese M
CNS Drugs; 2020 Apr; 34(4):425-432. PubMed ID: 32193826
[TBL] [Abstract][Full Text] [Related]
8. Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count.
Baharnoori M; Gonzalez CT; Chua A; Diaz-Cruz C; Healy BC; Stankiewicz J; Weiner HL; Chitnis T
Mult Scler Relat Disord; 2018 Feb; 20():51-57. PubMed ID: 29304497
[TBL] [Abstract][Full Text] [Related]
9. Dimethyl Fumarate Selectively Reduces Memory T Cells and Shifts the Balance between Th1/Th17 and Th2 in Multiple Sclerosis Patients.
Wu Q; Wang Q; Mao G; Dowling CA; Lundy SK; Mao-Draayer Y
J Immunol; 2017 Apr; 198(8):3069-3080. PubMed ID: 28258191
[TBL] [Abstract][Full Text] [Related]
10. Effects of dimethyl fumarate on lymphocyte subsets.
Berkovich R; Weiner LP
Mult Scler Relat Disord; 2015 Jul; 4(4):339-41. PubMed ID: 26195053
[TBL] [Abstract][Full Text] [Related]
11. Dimethyl fumarate induces a persistent change in the composition of the innate and adaptive immune system in multiple sclerosis patients.
Montes Diaz G; Fraussen J; Van Wijmeersch B; Hupperts R; Somers V
Sci Rep; 2018 May; 8(1):8194. PubMed ID: 29844361
[TBL] [Abstract][Full Text] [Related]
12. High CD4+:CD8+ ratios with herpes zoster infections in patients with multiple sclerosis on dimethyl fumarate.
Balshi A; Saart E; Pandeya S; Dempsey J; Baber U; Sloane JA
Mult Scler; 2023 Oct; 29(11-12):1465-1470. PubMed ID: 37572049
[TBL] [Abstract][Full Text] [Related]
13. Dimethyl fumarate treatment alters NK cell function in multiple sclerosis.
Smith MD; Calabresi PA; Bhargava P
Eur J Immunol; 2018 Feb; 48(2):380-383. PubMed ID: 29108094
[TBL] [Abstract][Full Text] [Related]
14. Dimethyl fumarate-related immune and transcriptional signature is associated with clinical response in multiple sclerosis-treated patients.
Sánchez-Sanz A; García-Martín S; Sabín-Muñoz J; Moreno-Torres I; Elvira V; Al-Shahrour F; García-Grande A; Ramil E; Rodríguez-De la Fuente O; Brea-Álvarez B; García-Hernández R; García-Merino A; Sánchez-López AJ
Front Immunol; 2023; 14():1209923. PubMed ID: 37483622
[TBL] [Abstract][Full Text] [Related]
15. Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis.
Gilmore W; Lund BT; Li P; Levy AM; Kelland EE; Akbari O; Groshen S; Cen SY; Pelletier D; Weiner LP; Javed A; Dunn JE; Traboulsee AL
J Neuroinflammation; 2020 Jun; 17(1):189. PubMed ID: 32539719
[TBL] [Abstract][Full Text] [Related]
16. Delayed lymphocyte re-population following discontinuation of dimethyl fumarate and after switching to other disease modifying drug therapies.
Khatri BO; Tarima SS; Essig B; Sesing J; Olapo T
Mult Scler Relat Disord; 2017 Nov; 18():60-64. PubMed ID: 29141823
[TBL] [Abstract][Full Text] [Related]
17. Factors associated with dimethyl fumarate-induced lymphopenia.
Sainz de la Maza S; Medina S; Villarrubia N; Costa-Frossard L; Monreal E; Tejeda-Velarde A; Rodríguez-Martín E; Roldán E; Álvarez-Cermeño JC; Villar LM
J Neurol Sci; 2019 Mar; 398():4-8. PubMed ID: 30658226
[TBL] [Abstract][Full Text] [Related]
18. Dimethyl fumarate-induced lymphocyte count drop is related to clinical effectiveness in relapsing-remitting multiple sclerosis.
Tsantes E; Curti E; Ferraro D; Lugaresi A; Baldi E; Montepietra S; Immovilli P; Simone AM; Mancinelli L; Strumia S; Vitetta F; Foschi M; Ferri C; Ferrarini C; Sola P; Granella F
Eur J Neurol; 2021 Jan; 28(1):269-277. PubMed ID: 32931130
[TBL] [Abstract][Full Text] [Related]
19. Cross-sectional analysis of peripheral blood mononuclear cells in lymphopenic and non-lymphopenic relapsing-remitting multiple sclerosis patients treated with dimethyl fumarate.
Lee CH; Jiang B; Nakhaei-Nejad M; Barilla D; Blevins G; Giuliani F
Mult Scler Relat Disord; 2021 Jul; 52():103003. PubMed ID: 34118574
[TBL] [Abstract][Full Text] [Related]
20. Increased multiple sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate: a case series.
Delgado S; Hernandez J; Tornes L; Rammohan K
BMC Neurol; 2021 Feb; 21(1):48. PubMed ID: 33530945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]